Europe PMC Funders Group
Author Manuscript
Leukemia. Author manuscript; available in PMC 2017 May 22.
Published in final edited form as:
Leukemia. 2017 February ; 31(2): 382–392. doi:10.1038/leu.2016.211.
Europe PMC Funders Author Manuscripts
Differentiation stage of myeloma plasma cells: biological and
clinical significance
B Paiva1, N Puig2, MT Cedena3, BG de Jong4, Y Ruiz3, I Rapado3, J Martinez-Lopez3, L
Cordon5, D Alignani1, JA Delgado1, MC van Zelm4,6, JJM Van Dongen4, M Pascual1, X
Agirre1, F Prosper1, JI Martín-Subero7, M-B Vidriales2, NC Gutierrez2, MT Hernandez8, A
Oriol9, MA Echeveste10, Y Gonzalez11, SK Johnson12, J Epstein12, B Barlogie12, GJ
Morgan12, A Orfao13, J Blade14, MV Mateos2, JJ Lahuerta3, and JF San-Miguel1 on behalf of
GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en
Hemopatías Malignas) cooperative study groups
1Clinica
Europe PMC Funders Author Manuscripts
Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA,
Pamplona, Spain 2Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de
Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca,
Spain 3Hospital 12 de Octubre, Madrid, Spain 4Department of Immunology, Erasmus MC,
University Medical Center, Rotterdam, The Netherlands 5Hospital Universitario y Politécnico La
Fe, Valencia, Spain 6Department of Immunology and Pathology, Monash University, Melbourne
VIC Australia 7Unidad de Hematopatología, Servicio de Anatomía Patológica, Hospital Clínic,
Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Barcelona, Spain 8Hospital Universitario de Canarias, Tenerife, Spain 9Institut Català d’Oncologia,
Institut Josep Carreras, Hospital Germans Trias I Pujol, Badalona, Spain 10Hospital de Donostia,
San Sebastian, Spain 11Hospital Universitario Josep Trueta, Girona, Spain 12Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
13Servicio General de Citometría, Centro de Investigación del Cancer (IBMCC-USAL, CSIC),
IBSAL and Department of Medicine, Universidad de Salamanca, Salamanca, Spain 14Hospital
Clínic, IDIBAPS, Barcelona, Spain
Abstract
The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in
multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we
demonstrated in healthy individuals (n = 20) that the CD19 − CD81 expression axis identifies
three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history,
immunoglobulin-production, and phenotype, consistent with progressively increased
differentiation from CD19+CD81+ into CD19 − CD81+ and CD19 − CD81 − BMPCs.
Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal
BMPC counterparts, 59% had fully differentiated (CD19 − CD81 −) clones, 38% intermediate-
Correspondence: Professor JF San Miguel, Clinica Universidad de Navarra; Centro de Investigacion Médica Aplicada (CIMA), Av.
Pio XII 36, Pamplona 31008, Spain. sanmiguel@unav.es.
Conflict of Interest
The authors declare no conflict of interest.
Paiva et al.
Page 2
Europe PMC Funders Author Manuscripts
differentiated (CD19 − CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter
patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker
for progression-free (HR: 1.7; P = 0.005) and overall survival (HR: 2.1; P = 0.006). Longitudinal
comparison of diagnostic vs minimal-residual-disease samples (n = 40) unraveled that in 20% of
patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We
also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs
retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show
distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we
shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated
PCs have dismal survival, which might be related to higher chemoresistant potential plus different
molecular and genomic profiles.
Introduction
Multiparameter flow cytometry (MFC) is currently considered a sensitive co-adjuvant test in
the diagnostic screening of patients with multiple myeloma (MM) to demonstrate bone
marrow (BM) clonality.1 Tumour plasma cells (PCs) from virtually all MM patients show
phenotypic aberrancies that allow for clear distinction between these and normal PCs;2
furthermore, the expression levels of some antigens are significantly associated with
differences in outcome.3–7 One example is CD19, whose expression has been found in 5–
10% of MM cases and correlated with inferior survival;3 however, the biological explanation
behind such correlation remains unknown. Recently, we showed that the expression of CD81
in clonal PCs is also an independent prognostic factor in MM,4 but similarly to CD19, there
is no knowledge on the biologic significance of CD81 expression in the surface of clonal
PCs.
Europe PMC Funders Author Manuscripts
Normal PC differentiation is characterized by the acquisition of secretory capacity, cellcycle exit and changes in both surface phenotype and gene expression.8 Accordingly, CD19,
which is a co-receptor of the B-cell receptor and is solely regulated by PAX5, becomes lost
in a subset of normal BMPCs after PAX5 down-regulation during B-cell into PC
differentiation.9,10 After the initial observation that CD19 expression was decreased in
mature PCs generated in vitro,11 most recent analyses suggested that CD19−CD38hiCD138+
PCs share similarities with murine long-lived PCs and could represent their human
counterpart.12,13 Since CD19 expression requires CD81,14 a tetraspanin widely expressed
at all stages of the B-cell lineage,4,15 it could be hypothesized that both markers might
contribute to identify unique PC subsets during the transition from less- into moredifferentiated BMPCs. In such cases, further investigations in MM would be warranted to
unravel whether clonal PCs follow a similar pattern of normal PC differentiation according
to CD19 − CD81 expression levels, and to determine the clinical sequelae of myeloma PCs’
differentiation stage.
Here, we started by showing that the combined expression of CD19 and CD81 identified
three unique BMPC subsets in healthy individuals with distinct functional and phenotypic
features, consistent with progressively increased differentiation from CD19+CD81+ into
CD19−CD81+ and CD19−CD81− normal BMPCs. Subsequently, we demonstrated that
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 3
Europe PMC Funders Author Manuscripts
myeloma PCs fit into such a model of normal BMPC differentiation, and that patients with
less-differentiated clones had dismal survival. PC differentiation is also related to therapyinduced selective pressure, through which less-differentiated PCs subclones become
enriched from diagnosis into minimal residual disease (MRD) stages in a subset of MM
patients. Most interestingly, less-differentiated PCs maintain the expression of genes related
to preceding B-cell stages, and show different mutation profiles as compared to fully
differentiated PC subclones within individual MM patients.
Materials and Methods
Patients, controls and samples
A total of 225 elderly, transplant-ineligible patients with newly diagnosed symptomatic MM
staged according to the International Myeloma Working Group criteria16 were prospectively
studied after inclusion in the PETHEMA/GEM2010MAS65 trial (NCT01237249). In all
cases, BM aspirates were collected at diagnosis and in 40 out of the 225 patients, also after
induction therapy for preplanned MRD monitoring. BM aspirates were additionally taken
from 20 healthy individuals (median age: 46 years; range: 19–64 years) to study the
functional and phenotypic characteristics of normal PCs. All samples were collected after
informed consent was given by each individual, according to the local ethical committees
and the Helsinki Declaration.
Multidimensional flow cytometry (MFC) immunophenotyping
Europe PMC Funders Author Manuscripts
Approximately 200 μl of ethylenediaminetetraacetic acid-anticoagulated BM aspirated
samples from newly diagnosed MM patients were immunophenotyped using two different
eight-colour combinations of monoclonal antibodies (MoAb) and a direct
immunofluorescence stain-and-then-lyse technique – (Pacific Blue (PacB)/Pacific Orange
(PacO)/fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/peridinin chlorophyll proteincyanin 5.5 (PerCP-Cy5.5)/PE-cyanin 7 (PE-Cy7)/allophycocyanin (APC)/APCH7): (i)
CD45/CD138/CD38/CD56/β2microglobulin/CD27/CD19/cyKappa/cyLambda; (ii) CD45/
CD138/CD38/CD28/CD27/CD19/CD117/CD81 following the EuroFlow guidelines17 to
identify clonal PCs, and characterize their pattern of expression for CD19 and CD81.
Patients with no reactivity for CD19 and < 10% CD81+ clonal PCs were classified as CD19CD81-, whereas those cases with < 50% CD19+ clonal PCs but CD81 expression (≥10%)
were classified as CD19-CD81+; all remaining patients showing ≥50% CD19+ clonal PCs
were classified as CD19+CD81+ (all of them were positive for CD81). After induction
therapy, a single eight-colour MoAb combination (PacB/PacO/FITC/PE/PerCP-Cy5.5/PECy7/APC/APCH7) with CD45/CD138/CD38/CD56/CD27/CD19/CD117/CD81 was used to
monitor MRD, and whenever persistent MRD was detected, the percentage of CD19+ and/or
CD81+ clonal PCs was determined to compare, at the individual-patient-level, with that
found at diagnosis. The same eight-colour MoAb combination was used to characterize the
BMPC compartment of the 20 healthy individuals. In five out of the former 20 cases, an
additional eight-colour MoAb combination (BV421/BV510/FITC/PE/PerCP-Cy5.5/PECy7/APC/APCH7) with CD138/CD27/cyIgM+cyIgA/cyIgA+cyIgG/CD38/CD19/cyKappa/
CD81 was stained to quantify the cytoplasmic (cy) immunoglobulin (Ig) heavy chain
distribution in different PC subsets according to CD19 − CD81 expression. Data acquisition
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 4
was performed for approximately 106 leukocytes/tube in an FACSCantoII flow cytometer
(Becton Dickinson – BD – San Jose, CA, USA) using the FACSDiva 6.1 software (BD).
Data analysis was performed using the Infinicyt software (Cytognos SL, Salamanca, Spain).
Quantitation of replication history
Europe PMC Funders Author Manuscripts
B-lymphocyte precursors, transitional, naive and memory B-cells, CD19+ and CD19− PCs
were FACS-sorted (FACSAria II, BD; purity ≥97%) from BM samples of healthy
individuals (n = 5), according to their respective phenotypic characteristics as described
elsewhere.18–20 The replication history of B-lymphocytes and PCs was determined using
the κ-deleting recombination excision circle assay, which is based on the quantification of
coding joints and signal joints of an Ig-deleting rearrangement (intron RSS-Kde) by realtime quantitative PCR.20 Primers and probes were designed to specifically amplify the
intronRSS-Kde rearrangements (coding joint) and the corresponding signal joint using
TaqMan-based real-time quantitative PCR from DNA isolated from FACS-sorted cell
subsets.20 The real-time quantitative PCR mixture of 25 μl contained TaqMan Universal
MasterMix (Applied Biosystems, Waltham, MA, USA), 900 nM of each primer, 100 nM of
each FAM-TAMRA-labelled probe, 50 ng of DNA and 0.4ng BSA, and was run on the
ABIPRISM 7700 sequence detection system (Applied Biosystems).20
Cell cycle analyses
The proliferation index of different normal PC subsets according to CD19 − CD81
expression was analysed in BM samples from five healthy individuals using five-colour
staining for nuclear DNA and four cell surface antigens (CD19–PacB/CD45–PacO/CD38–
FITC/CD81–PE) as described elsewhere.21
Single-cell multidimensional phenotyping
Europe PMC Funders Author Manuscripts
Bone marrow aspirates from healthy individuals (n = 10) were immunophenotyped using
four different eight-colour combinations of MoAb: (PacB, PacO, FITC, PE, PerCP-Cy5.5,
PE-Cy7, APC, alexafluor 700 (AF700)): (i) CD29, CD45, CD11a, β7, CD79b, CD49d,
CD19, CD38; (ii) CD11c, CD45, CD41a, CD49e, CD33, CD117, CD19, CD38; (iii) CD20,
CD45, CD81, CD54, CD138, CD56, CD19, CD38; and (iv) HLA-DR, CD45, CD44,
CXCR4, CD27, CD28, CD19, CD38. The expression of all 23 phenotypic markers was
analysed at the single PC-level and compared between the CD19+CD81+, CD19−CD81+ and
CD19−CD81− subsets, using the merge and calculation functions of the Infinicyt software as
described elsewhere.22–24
Fluorescence-in-situ-hybridization (FISH) and deep-targeted sequencing
FISH was performed at diagnosis on immunomagnetic-enriched PCs from 169 out of the
225 cases with available phenotypic data. DNA from two PC clones FACS-purified
according to their differentiation status from six newly diagnosed MM patients was analysed
including the corresponding germline samples. DNA was extracted from cells using AllPrep
DNA/RNA Micro Kit, Qiagen (Hilden, Germany). Targeted gene sequencing was performed
using 20 ng of input DNA and applying the MM Mutation Panel Version 2.0 (M3P 2.0).
Targeted panel consists of 1271 amplicons from 77 genes commonly mutated in MM.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 5
Enriched templates were sequenced using semiconductor technology (Ion Proton, Life
Technologies, Waltham, MA, USA) and analysed with Ion Reporter Software v4.4 (Life
Technologies). A median of 1700x depth coverage was obtained. Mutation calls were
considered positive when called by ≥5% variant reads, with a minimum depth coverage of
10 reads.
Europe PMC Funders Author Manuscripts
Gene expression profiling (GEP)
A total of 71 newly diagnosed MM patients screened at the University of Arkansas for
Medical Sciences and with simultaneously available information on CD19 and CD81
immunophenotypic patterns of expression and GEP were included in this analysis. An
aliquot of BM aspirate was collected to isolate CD138+ PCs with immunomagnetic bead
selection (autoMACS; Miltenyi Biotec, Bergisch Gladbach, Germany), as described
elsewhere.25 Purity of PC was monitored by flow cytometry and was ≥85%. Total RNA
was used to measure GEP with Affymetrix U133 Plus 2.0 microarrays. Differentially
expressed genes between classes were identified using the Significant Analysis of
Microarrays algorithm. Analyses were performed using BRB-ArrayTools (version 4.4.1)
developed by Dr Richard Simon and the BRB-ArrayTools Development Team, available at
http://linus.nci.nih.gov/BRB-ArrayTools.html.
DNA methylation studies
We used the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) for bisulfite
conversion of 500 ng genomic DNA. Bisulfite-converted DNA was hybridized onto the
HumanMethylation 450 K BeadChip kit (Illumina, San Diego, CA, USA). Data from the
450 k Human Methylation Array were analysed as described previously.26
Statistical analysis
Europe PMC Funders Author Manuscripts
Correlation studies between PC subset distribution and age were performed using the
Pearson test. The Wilcoxon signed rank test was used to evaluate the statistical significance
of the percentage of each PC subset in the distinct phases of the cell cycle, as well as for the
replication history of each PC subset. Conversely, the Friedman test was used to compare the
distribution according to the heavy-chain Ig isotype across the different PC subsets. The
Mann–Whitney U and the Kruskal–Wallis tests were used to estimate the statistical
significance of differences observed between two or more groups, respectively. Survival was
analysed by the Kaplan–Meier method, and differences between curves were tested for
statistical significance with the two-sided log-rank test. Progression-free survival (PFS) was
defined as the time from diagnosis to disease progression or death from any cause, and
overall survival (OS) as time from diagnosis to death from any cause. A multivariate Cox
proportional hazard model was developed to explore the independent value of significant
variables on the univariate analysis, and variables were retained in the model for levels of
significance P < 0.05.The SPSS software (version 20.0; IBM, Armonk, NY, USA) was used
for all statistical tests.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 6
Results
Combined expression of CD19 and CD81 identifies three unique normal BM PC subsets
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
We first determined the distribution of the CD19+CD81+, CD19−CD81+ and CD19−CD81−
subsets within total BMPCs from healthy individuals; overall, the CD19+CD81+ subset
accounted for the majority of PCs (median of 79% within the BMPC compartment),
followed by the CD19−CD81+ and CD19−CD81− subsets (14 and 5%, respectively).
However, when we compared the distribution of each subset within the BMPC compartment
across different age decades, we noted that while CD19−CD81+ and CD19−CD81− PCs were
almost absent among healthy individuals aged 10–20 years, their frequency progressively
increased from younger to older individuals (Figure 1a). Accordingly, there was a significant
(P ⩽ 0.006) correlation between age and the distribution of the CD19+CD81+, CD19−CD81+
and CD19−CD81− subsets (Figure 1a), suggesting that CD19+CD81+ normal BMPCs appear
earlier in the development of antibody responses, whereas CD19−CD81+ and CD19−CD81−
PCs accumulate in the BM later in life. Since during PC differentiation acquisition of
secretory capacity is accompanied by progressive cell cycling exit, we subsequently
explored the distribution of the CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets
within G0/G1 and S-phase/G2M normal BMPCs. As expected, the majority of BM PCs were
in G0G1 (data not shown), but while the relative distribution of all three CD19+CD81+,
CD19−CD81+ and CD19−CD81− subsets in G0G1 was inside the normal ranges described
above, there were virtually no CD19−CD81− PCs in S-phase/G2M (Figure 1b; P = 0.03).
Thus, CD19−CD81− normal PCs were not only enriched in the BM of elderly healthy
individuals, but also showed virtually no proliferation, suggesting that among CD19− PCs,
those lacking CD81 could be more differentiated than CD19−CD81+ BMPCs. Additional
analysis was performed to assess the replication history of CD19+CD81+ and total CD19−
BMPCs, since it was not possible to purify sufficient cells numbers for the κ-deleting
recombination excision circle assay from CD19−CD81+ and CD19−CD81− BMPCs
separately (Figure 1c); that notwithstanding, we confirmed that PCs have a superior median
number of cell cycles compared to B-lymphocytes (P = 0.04), but also showed that within
the BMPC compartment, the median number of cell cycles in CD19− PCs was slightly
superior to that of CD19+ PCs (P = 0.08). Additionally, there was a trend (P = 0.07) for an
altered distribution of Ig heavy-chain isotypes between PC subsets according to their CD19
− CD81 expression, with progressively decreasing frequencies of IgA+ PCs counterbalanced
with increasing numbers of IgG+ PCs along the respective CD19+CD81+, CD19−CD81+ and
CD19−CD81− BMPC subsets (Figure 1d). Further phenotypic differences were observed
after single-cell analysis of 21 markers within the CD19 − CD81 phenotypic pathway, with
decreasing mean fluorescence intensity of CD27, CD38, CD44 and CD54 combined with
progressively increased expression of CD28 and CD56 being observed along the
CD19+CD81+, CD19−CD81+ and CD19−CD81− BMPC subsets (Figure 1e). Overall, our
results indicate that the combined CD19 − CD81 pattern of expression identifies three
BMPC subsets with singular functional and phenotypic characteristics, consistent with an
accumulation of long-lived, less active and fully differentiated PCs from the CD19+CD81+
and CD19−CD81+ into the CD19−CD81− BMPC subsets.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 7
Clinical sequelae of the differentiation stage of myeloma PC clones
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
After demonstrating the existence of three well-defined normal BMPC subsets with distinct
differentiation, we sought to determine how myeloma PC clones fit in such a model of
normal BMPC differentiation. Upon specific analysis of the CD19 − CD81 pattern of
expression in clonal PCs from 225 newly diagnosed MM patients, we found that more than
half (132/225; 59%) had clonal PCs that phenotypically matched the fully differentiated
normal PC counterpart (that is: CD19−CD81−); conversely, 86 out of the 225 patients (38%)
displayed intermediate-differentiated myeloma PCs (that is: CD19−CD81+), whereas only
seven cases (3%) showed clonal PCs for which the normal counterpart would correspond to
the less-differentiated BMPC subset (that is: CD19+CD81+). Interestingly, patients with lessand intermediately differentiated clonal PCs had a different phenotypic profile vs cases with
a fully differentiated PC phenotype (Table 1), with significantly less frequent CD28+ and
CD117+ expression; conversely, CD45 positivity was more frequent among patients with
less-differentiated PC clones (Table 1). Furthermore, we noted a trend (P = 0.07) for higher
frequencies of cytogenetic abnormalities (that is: t(IGH), +1q, del(13q), and/or del(17p))
from patients with less-into intermediate- and fully differentiated PCs (Table 2); in fact,
cases with less-differentiated clones only showed +1q, and no IGH translocations nor
del(13q) nor del(17p). Patients with less-and intermediately differentiated clonal PCs
achieved lower MRD-negative rates as compared to cases with a more mature PC phenotype
(25 and 20 vs 40%; P = 0.03). Upon investigating if the differentiation stage of myeloma PC
clones influenced patients’ prognosis, we noted that progression-free survival and overall
survival of cases in less- and intermediate-differentiation stages was significantly inferior as
compared to patients with fully differentiated CD19−CD81− myeloma PC clones (Figures 2a
and b). The treatment arm had no impact in patients’ outcomes according to PC
differentiation (data not shown). Multivariate analysis of baseline prognostic factors for
survival including the differentiation stage of clonal PCs plus patients’ age, ISS and FISH
cytogenetics showed that the best combination of independent predictive parameters for
progression-free survival and overall survival were PC differentiation and FISH cytogenetics
(Table 3). Accordingly, the differentiation stage of clonal PCs continued to be prognostically
relevant for progression-free survival and overall survival when the analysis was restricted to
cytogenetically defined standard-risk cases (Figures 2c and d), suggesting that the presence
of less-differentiated myeloma PC clones identifies a subgroup of patients with more
aggressive disease despite standard-risk cytogenetic profiles.
Less-differentiated PC clones may become predominant at the MRD stage
Since the differentiation stage of clonal PCs at baseline was intrinsically related to patients’
response to therapy and survival, we subsequently evaluated the in vivo chemoresistant
profile of different myeloma PC clones according to their differentiation stage, by
performing a longitudinal comparison of the CD19 − CD81 pattern of expression in clonal
PCs at diagnosis (baseline) vs after treatment during MRD monitoring (the chemoresistant
subclone) in 40 MM patients. Overall, we found that while the expression of CD19 remained
mostly stable between baseline and MRD (Figure 3a), there was a significant increase in the
percentage of CD81+ chemoresistant clonal PCs after therapy (mean of 31 vs 21% at
baseline, P = 0.04). Accordingly, 30/40 (75%) patients displayed the same differentiation
stage during baseline and MRD monitoring (16 corresponding to the fully differentiated PC
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 8
Europe PMC Funders Author Manuscripts
subset (that is: CD19−CD81−) and 14 to the intermediate stage (that is: CD19−CD81+)),
whereas 10/40 (25%) patients showed clonal selection of PCs with altered differentiation
upon therapy-induced selective pressure (Figure 3b). Namely, eight cases with fully
differentiated phenotypes at diagnosis showed intermediate stage chemoresistant clonal PCs
after therapy; conversely, the remaining two patients transitioned from a CD19−CD81+ into
a CD19−CD81− phenotype (Figure 3b). These results demonstrate that in approximately
one-fourth of MM patients there might be clonal selection upon therapy of PC subsets with a
distinct differentiation stage to that observed in the majority of myeloma PCs at diagnosis;
such clonal dynamics usually favour less-differentiated PC subclones.
Mutation profiles of intraclonal heterogeneity according to PC differentiation
Europe PMC Funders Author Manuscripts
Upon observing that in selected patients less-differentiated PC subclones became
predominant under therapeutic pressure, we decided to investigate whether less- and fully
differentiated PC subclones could eventually display different genomic profiles. In order to
address this hypothesis, we investigated the presence of mutations in PC subclones sorted
according to their differentiation stage within individual patients (n = 6), by using a
comprehensive panel covering 77 genes. While one case had no detectable mutations among
those tested in any of the FACS-purified CD19−CD81+ and CD19−CD81− PC subsets (#1;
Figure 4a), the five remaining patients had detectable mutations and their pattern differed
within PC subclones sorted according to their differentiation stage. Namely, in case#2
CD19−CD81+ myeloma PCs displayed mutations in SP140 that were not present among
more differentiated CD19−CD81− PCs. Similarly, patient#3 had a mutation in epidermal
growth factor receptor among less-differentiated tumour cells while absent in intermediateand fully differentiated clones. Patient#4 showed a mutation in DIS3 that was
simultaneously present in CD19−CD81+ and CD19−CD81− myeloma PCs; however,
intermediate-differentiated cells had an additional mutation in IKZF3. Cases #5 and #6
showed the highest differences between the mutation profiles, with mutually exclusive
mutations among intermediate- vs fully differentiated myeloma in both cases. Overall, these
results suggest that tumour heterogeneity, dissected according to PC differentiation on
phenotypic grounds, may uncover the presence of subclones with different mutation profiles.
GEP of MM patients according to the differentiation stage of myeloma PC clones
After demonstrating that myeloma PCs followed the same model of differentiation as
observed in BMPCs from healthy individuals, and that such a model had a clear implication
in patients’ survival, we decided to investigate if the differentiation stage of myeloma PC
clones would underlie different mRNA expression. Our results showed that newly diagnosed
MM patients with less-differentiated clonal PCs (that is: CD19+CD81+; n = 8) displayed 39
deregulated genes as compared to cases with intermediate-differentiation (that is:
CD19−CD81+; n = 33) (Supplementary Excel File 1). CD19 mRNA expression was
consistent with that observed on phenotypic grounds and was down-regulated among
CD19−CD81+ patients; most-interestingly, down-regulation of other B-cell related genes
such as CD79A, MS4A1 (CD20) and PAX5 was also observed. PTPRCAP, which stabilizes
the expression of CD45, the pre-B-lymphocyte 3 protein coding gene VPREB3, TNFSF8
and CCND1 were also found to be down-regulated among CD19−CD81+ patients. Although
no significantly deregulated genes were observed upon comparing patients with
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 9
Europe PMC Funders Author Manuscripts
CD19−CD81+ vs CD19−CD81− (n = 28) phenotypes, gene set enrichment analysis showed
that patients with intermediate-differentiated CD19−CD81+ PCs had significantly upregulation of cell cycle, nucleotide excision repair and DNA replication pathways as
compared to those with fully differentiated CD19−CD81− PCs, which is consistent with the
higher proliferative potential of the former PC subset. Conversely, patients with fully
differentiated PCs showed down-regulation of pathways related to protein processing in ER,
among others (Supplementary Excel File 2). The comparison between patients with less- vs
fully differentiated (that is: CD19+CD81+ vs CD19−CD81−) PCs showed up-regulation of
FCRLB, MS4A1 (CD20), CTGF, BEND5 and CD81 in less-differentiated clones
(Supplementary Excel File 1). Overall, these results confirm a correlation between the
phenotype and the GEP of PCs, but also that phenotypically less-differentiated
CD19+CD81+ myeloma clones retain higher expression of genes associated with preceding
B-cell stages.
Discussion
Europe PMC Funders Author Manuscripts
In other hematological malignancies such as acute myeloid leukemia, it is current practice to
classify blasts according to their differentiation stage, and the concept of cellular plasticity
with more immature clones being typically enriched at the MRD and relapse stages has been
recognized.27 In MM, it has recently been suggested that a progenitor organization exists
within clonal PCs that recapitulates maturation stages between B-cells and PCs, and may
contribute to in vitro chemoresistance.28 However, there is no accurate knowledge on the
myeloma PC differentiation pathway, nor how these correlate with patients’ clinical
behaviour; in fact, information on the correct identification of less- vs fully differentiated
normal BMPCs is yet very limited.12,13 Here, we showed the existence of three welldefined maturation stages in both normal and clonal BMPCs identified through the CD19 −
CD81 expression axis, and that MM patients harbouring less-differentiated PCs have dismal
survival. We also showed that the level of PC differentiation in MM could be related, at least
in part, to different chemoresistant potential together with different molecular and genomic
profiles.
The variable half-life of different serum antibodies (for example: in response to measles and
mumps vs influenza viruses)29 is consistent with specific survival patterns among unique
PC subsets, with long-lived PCs being responsible for maintaining such antibody titres for a
life-span of several years or decades.30 Two recent studies have characterized CD19−
normal PCs and concluded that these are specifically enriched in the BM and display unique
morphological, transcriptomic and phenotypic features consistent with increased
differentiation as compared to CD19+ PCs;12,13 accordingly, affinity for viral antigens to
which healthy individuals had not been exposed for more than 40 years have been
exclusively detected among CD19− BMPCs.12 Such observations open new research areas
to further investigate the features of specific normal and pathological PC subsets according
to their differentiation.12 Thus, reinforced by the recent confirmation31 of the regulatory
role of CD81 over CD19 within the B-cell co-receptor,14,32–34 we decided to investigate if
the CD19 − CD81 pattern of expression could help to further dissect unique PC
differentiation subsets. Our results are consistent with those reported by Halliley et al.12 and
Mei et al.13 and show that in healthy individuals, CD19− BMPCs are less proliferative and
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 10
Europe PMC Funders Author Manuscripts
are enriched in IgG secreting cells, as compared to the CD19+ subset. The notion that
CD19− BMPCs are more differentiated than the positive subset was further confirmed in our
study after demonstrating that the former have higher replication history. However, we also
showed that CD19− BMPCs can be further dissected into CD19−CD81+ and CD19−CD81−
subsets, and that the latter represent the most differentiated compartment among total
BMPCs.
Europe PMC Funders Author Manuscripts
Longevity of PCs in BM is restricted by competition for niche space35 and in this
competitive model, PC intrinsic features likely contribute to determine their life span by
controlling PC function and niche affinity.11 Here, CD28 and CD56 expression was found
to be progressively increased from less- CD19+CD81+ into more-differentiated
CD19−CD81+ and CD19−CD81− BMPCs; accordingly, long-term humoral immunity has
been reported to depend on the PC-intrinsic function of CD28 signalling down-stream of the
CD28 Vav motif that regulates BLIMP1.36 CD56 is likely contributing to stronger PC
adhesion to BM stromal niches. Most interestingly, pathological PCs in MM displayed a
similar phenotypic behaviour as compared to normal PCs, and patients with fully
differentiated clones also showed higher expression of CD28 and CD56, as well as CD38low.
The fact that mature CD19−CD81− normal BMPCs are absent in infants aged 5–7 months13
but progressively accumulate later in life as shown here, is also a remarkable coincidence
with the fact that monoclonal gammopathy of undetermined significance and MM typically
develop in the elderly, and that more than half of the patients (59%) display PC clones that
phenotypically overlap with fully differentiated normal PCs. Since loss of CD19 and CD81
expression was observed in both normal and tumour PC differentiation, we hypothesized
that their regulation was under epigenetic grounds. Thus, we analysed DNA methylation
levels around the CD81 gene (in its upstream CpG island shore region, CpG island, gene
body region close to CpG island (Gene Body 1) and the rest of gene body (Gene Body 2)) in
three MM cell lines with variable levels of CD81 expression (Figure 5). While no
differences in DNA methylation in the CpG island shore and Gene Body 2 regions were
observed, the methylation levels in the CpG island and Gene Body region 1 showed a clear
correlation with CD81 expression, suggesting that these regions contain regulatory elements
that control CD81 expression. Accordingly, methylation in the CpG island and CD81
expression were inversely correlated. In contrast, levels of DNA methylation in the Gene
Body region 1 were positively correlated with gene expression. This dual pattern of negative
and positive association between gene expression and DNA methylation depending on the
region analysed has been previously observed,37 and underlines that the function of DNA
methylation is genomic context dependent.38
The notion that PCs represent the terminally differentiated end-stage of the B-cell lineage
has likely contributed to a deficiency in knowledge about the levels of phenotypic plasticity
and maturation of clonal PCs in MM.28,39 Here, we show that up to 41% of MM patients
display at diagnosis PC clones corresponding to less-differentiated normal PC counterparts,
including 3% corresponding to the more immature CD19+CD81+ subset. Most interestingly,
the latter maintain high expression of genes typically related to mature B-cell stages such as
PAX5, CD20, CD79b, VPREB3, TNFSF8 and CCND1 as revealed by comparing their GEP
against that of PCs obtained from patients with intermediate- (CD19−CD81+) and fully
differentiated phenotypes (CD19−CD81−). These results suggest that the proposed
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 11
Europe PMC Funders Author Manuscripts
phenotypic differentiation model of myeloma PCs is corroborated at the molecular level,
similarly to what has been recently shown in normal BMPCs from healthy individuals.12
Importantly, MM patients harbouring less-differentiated PC clones had dismal outcome with
a median survival of approximately 1 year. Accordingly, the differentiation status of clonal
PCs emerges as a new and independent prognostic marker in MM, complementary to
patients’ cytogenetic profile. In fact, patients’ characterization according to PC
differentiation status allowed the identification of a subset of cases with dismal survival
albeit standard-risk cytogenetics. It should be noted that the small number of cases
harbouring less-differentiated PC clones limits the robustness of the statistical comparison
between groups (particularly regarding survival analyses), and these results should be
reproduced in larger series of patients (for example: GEM2005MENOS65 and
GEM2005MAS65 clinical trials; Supplementary Figure 1). That notwithstanding, the
availability of multiple novel and effective drugs combined with the advent of highthroughput (cellular and molecular) techniques, may help to identify small patient subgroups
with a unique biology that could benefit from tailored treatment (for example: anti-CD19
CAR T-cells40 for cases with less-differentiated myeloma PCs).
Europe PMC Funders Author Manuscripts
The identification of more immature cancer (stem) cells has been historically pursued to
justify unexplainable relapses, particularly among patients achieving CR.41,42 However,
relapses among MM patients in CR are now better understood and predicted with the advent
of MRD monitoring, which have shown an intrinsic correlation between the persistence of
residual clonal PCs after therapy (that is: MRD) and inferior survival.43–46 Here, we used a
novel approach to understand ultra-chemoresistance by performing in individual patients
longitudinal comparisons between clonal diversity according to PC differentiation at
diagnosis vs MRD.22 Hence, we showed that therapeutic pressure may lead to in vivo
selection of specific PC subsets, and that in approximately one-fourth of MM patients such
clonal selection favoured less-differentiated PC subclones. Thus, further studies are
warranted to establish a clear relationship between the extent of PC differentiation and their
chemoresistant potential. On a different note, these results may also reflect previously
unknown levels of cellular plasticity in vivo,47 by which PCs can transition from mature
into more immature stages (and vice-versa) upon therapeutic pressure. The observations that
CD81 expression is epigenetically regulated together with the lack of a clear pattern of
accumulating mutations in FACS-purified immature vs mature PCs subclones from
individual patients, would support such phenomenon of cellular plasticity. Thus, establishing
the temporal acquisition of mutations and genetic abnormalities in less- vs moredifferentiated PC clones should be investigated in future studies. Interestingly, these findings
also unravel that detailed characterization of the MRD PC compartment might be as
informative as more conventional MRD quantitation to predict patients’ outcome (for
example: survival of an MRD-positive patient displaying immature PC clones may be poorer
than other MRD-positive cases).23,48
In summary, we shed new light into normal and tumour PC plasticity, with the identification
of three well-defined differentiation subsets in both healthy individuals and MM patients,
respectively. The demonstration that tumour PC differentiation might be related to unique
chemoresistant, molecular and mutation profiles highlights its importance in the
prognostication and monitoring of MM patients.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 12
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
Europe PMC Funders Author Manuscripts
The authors acknowledge all the participants of the Spanish Myeloma Group. This study was supported by the
Cooperative Research Thematic Network grants RD12/0036/0048, RD12/0036/0058, RD12/0036/0046,
RD12/0036/0068, RD12/0036/0069, and RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence);
Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria
(FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09-/01897/01370; PI13/01469, PI14/01867, G03/136; Sara
Borrell: CD13/00340 and CD12/00540); Fundació La Marató de TV3 (20132130-31-32) and Asociación Española
Contra el Cáncer (GCB120981SAN). The study was also supported internationally by the International Myeloma
Foundation (IMF) Junior Grant, the Black Swan Research Initiative of the IMF, the Multiple Myeloma Research
Foundation research fellow award, the Qatar National Research Fund (QNRF) Award No. 7-916-3-237, Marie Curie
(LincMHeM-330598), the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV),
Leukemia Research Foundation and the European Research Council (ERC) 2015 Starting Grant.
References
Europe PMC Funders Author Manuscripts
1. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus
recommendations for standard investigative workup: report of the International Myeloma Workshop
Consensus Panel 3. Blood. 2011; 117:4701–4705. [PubMed: 21292778]
2. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H, et al. Immunophenotype of
normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in
multiple myeloma. Cytometry B Clin Cytom. 2015; 90:61–72. [PubMed: 26100534]
3. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, et al. Prognostic
value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative
study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008; 26:2737–
2744. [PubMed: 18443352]
4. Paiva B, Gutierrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L, et al. Clinical
significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic
multiple myeloma patients. Leukemia. 2012; 26:1862–1869. [PubMed: 22333880]
5. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, et al. The phenotype of
normal, reactive and malignant plasma cells. Identification of ‘many and multiple myelomas’ and of
new targets for myeloma therapy. Haematologica. 2006; 91:1234–1240. [PubMed: 16956823]
6. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, et al. Utility of flow cytometry
immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry
B Clin Cytom. 2010; 78:239–252. [PubMed: 20155853]
7. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the
European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related
disorders. Haematologica. 2008; 93:431–438. [PubMed: 18268286]
8. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;
5:230–242. [PubMed: 15738953]
9. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and
function. Nat Immunol. 2007; 8:463–470. [PubMed: 17440452]
10. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target
for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992; 12:2662–2672. [PubMed:
1375324]
11. Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, Davison A, et al. In vitro generation of
long-lived human plasma cells. J Immunol. 2012; 189:5773–5785. [PubMed: 23162129]
12. Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, et al. Long-lived plasma
cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow.
Immunity. 2015; 43:132–145. [PubMed: 26187412]
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 13
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
13. Mei HE, Wirries I, Frolich D, Brisslert M, Giesecke C, Grun JR, et al. A unique population of IgGexpressing plasma cells lacking CD19 is enriched in human bone marrow. Blood. 2015; 125:1739–
1748. [PubMed: 25573986]
14. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, et al. CD81 gene defect in
humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010;
120:1265–1274. [PubMed: 20237408]
15. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, et al. Aberrant
expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its
correlation with normal B-cell maturation. Leukemia. 2005; 19:1376–1383. [PubMed: 15931266]
16. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International
uniform response criteria for multiple myeloma. Leukemia. 2006; 20:1467–1473. [PubMed:
16855634]
17. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al.
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of
normal, reactive and malignant leukocytes. Leukemia. 2012; 26:1908–1975. [PubMed: 22552007]
18. Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, et al. Human peripheral
blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010; 78(Suppl
1):S47–S60. [PubMed: 20839338]
19. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et
al. Human memory B cells originate from three distinct germinal center-dependent and independent maturation pathways. Blood. 2011; 118:2150–2158. [PubMed: 21690558]
20. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJ. Replication history of B
lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J
Exp Med. 2007; 204:645–655. [PubMed: 17312005]
21. Paiva B, Paino T, Sayagues JM, Garayoa M, San-Segundo L, Martin M, et al. Detailed
characterization of multiple myeloma circulating tumor cells shows unique phenotypic,
cytogenetic, functional, and circadian distribution profile. Blood. 2013; 122:3591–3598. [PubMed:
24072855]
22. Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, et al. Phenotypic and genomic
analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand
chemoresistance. Blood. 2016; 127:1896–1906. [PubMed: 26755711]
23. Paino T, Paiva B, Sayagues JM, Mota I, Carvalheiro T, Corchete LA, et al. Phenotypic
identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and
clonogenic potential. Leukemia. 2015; 29:1186–1194. [PubMed: 25388955]
24. Paiva B, Corchete LA, Vidriales MB, Garcia-Sanz R, Perez JJ, Aires-Mejia I, et al. The cellular
origin and malignant transformation of Waldenstrom macroglobulinemia. Blood. 2015; 125:2370–
2380. [PubMed: 25655603]
25. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, et al. Improvement in long-term
outcomes with successive Total Therapy trials for multiple myeloma: are patients now being
cured? Leukemia. 2013; 27:226–232. [PubMed: 22705990]
26. Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, et al. Whole-epigenome analysis
in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res.
2015; 25:478–487. [PubMed: 25644835]
27. Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a ‘moving target’
for detection of residual disease. Cytometry B Clin Cytom. 2014; 86:3–14. [PubMed: 24151248]
28. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1snegative tumor B cells and pre-plasmablasts mediate therapeutic protea-some inhibitor resistance
in multiple myeloma. Cancer Cell. 2013; 24:289–304. [PubMed: 24029229]
29. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine
antigens. N Engl J Med. 2007; 357:1903–1915. [PubMed: 17989383]
30. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;
388:133–134. [PubMed: 9217150]
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 14
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
31. Vences-Catalan F, Kuo CC, Sagi Y, Chen H, Kela-Madar N, van Zelm MC, et al. A mutation in the
human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19
maturation and cell surface expression. J Clin Immunol. 2015; 35:254–263. [PubMed: 25739915]
32. Cherukuri A, Carter RH, Brooks S, Bornmann W, Finn R, Dowd CS, et al. B cell signaling is
regulated by induced palmitoylation of CD81. J Biol Chem. 2004; 279:31973–31982. [PubMed:
15161911]
33. Cherukuri A, Shoham T, Sohn HW, Levy S, Brooks S, Carter R, et al. The tetraspanin CD81 is
necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into
signaling-active lipid rafts. J Immunol. 2004; 172:370–380. [PubMed: 14688345]
34. Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe JC, Tedder TF, et al. The tetraspanin
CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum
compartment. J Immunol. 2003; 171:4062–4072. [PubMed: 14530327]
35. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by
bone marrow stroma. Nat Rev Immunol. 2010; 10:193–200. [PubMed: 20154734]
36. Rozanski CH, Utley A, Carlson LM, Farren MR, Murray M, Russell LM, et al. CD28 promotes
plasma cell survival, sustained antibody responses, and BLIMP-1 upregulation through its distal
PYAP proline motif. J Immunol. 2015; 194:4717–4728. [PubMed: 25833397]
37. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, et al. Epigenomic analysis detects
widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;
44:1236–1242. [PubMed: 23064414]
38. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev
Genet. 2012; 13:484–492. [PubMed: 22641018]
39. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, et al. Clinical drug resistance
linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple
myeloma. Blood. 2013; 121:318–328. [PubMed: 23169779]
40. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen
receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015; 373:1040–1047.
[PubMed: 26352815]
41. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of
clonogenic multiple myeloma cells. Blood. 2004; 103:2332–2336. [PubMed: 14630803]
42. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, et al. Hedgehog
signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci
USA. 2007; 104:4048–4053. [PubMed: 17360475]
43. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, et al. Critical evaluation of
ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative
analysis with flow cytometryBlood. 2014; 28:391–397.
44. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. Highrisk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict
unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Blood. 2012; 119:687–691. [PubMed: 22128143]
45. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of
deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;
123:3073–3079. [PubMed: 24646471]
46. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal
residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log
reduction. Blood. 2015; 125:1932–1935. [PubMed: 25645353]
47. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation
into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res. 2005; 11:7599–
7606. [PubMed: 16278377]
48. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual
disease in multiple myeloma. Blood. 2015; 125:3059–3068. [PubMed: 25838346]
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 15
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
Figure 1.
Bone marrow (BM) normal plasma cell (PC) subsets according to the CD19 − CD81
expression axis. (a) Age-related changes in the distribution of BM normal PC subsets. The
percentage of the CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets within total BM
PCs from each healthy donor (n = 20) was determined, and median values per subset for
each age decade are represented by light, intermediate and dark blue areas, respectively.
Linear regression between individuals’ age and the respective percentage for each PC subset
is also shown. (b) Proliferative potential of the different BM normal PC subsets. The
percentage of the CD19+CD81+ (light blue), CD19−CD81+ (intermediate blue) and
CD19−CD81− (dark blue) subsets within total BM PCs from healthy donor (n = 5) in G0/G1
and S-phase/G2M phases of the cell cycle is shown. (c) Quantification of the replication
history of progressively maturing BM B cell and PC subsets from healthy individuals using
κ-deleting recombination excision circles. The line in the middle and vertical lines
correspond to the median value and both the 10th and 90th percentiles, respectively, for the
ΔCT between the coding joint and the signal joint in FACS-sorted B-cell precursors,
transitional, naïve and memory B-cells, CD19+ and CD19− PCs from BM samples of
healthy individuals (n = 5). (d) Immunoglobulin (Ig) heavy chain isotype distribution of the
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 16
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
different BM normal PC subsets. After PC identification according to their bright CD38 and
CD138 expression and unique scatter characteristics, cyIgG+ PCs were defined as those
showing reactivity in the PE channel (cyIgA+cyIgG) but not in the FITC channel (cyIgM
+cyIgA), whereas cyIgA+ PCs were defined as those showing (diagonal) double-staining in
the FITC+PE channels; cyIgM+ PCs were defined by reactivity in the FITC channel but not
in PE. The percentage of cytoplasmic IgG, IgA and IgM is shown within the respective
CD19+ CD81+, CD19−CD81+ and CD19−CD81− subsets. (e) Immunophenotypic protein
expression profiles of the different BM normal PC subsets. Due to the existence of five
parameters measured in common for each aliquot (CD38, CD45, CD19, forward light scatter
– FSC and sideward light scatter – SSC), it was possible to define the PC compartment in
each aliquot and fuse the different data files corresponding to the four different eight-colour
MoAb combinations studied per sample into a single data file containing all information
measured for that sample, using the merge function of the Infinicyt software. For any single
PC in each eight-colour MoAb combination, this included data about those antigens that
were measured directly on it and antigens that were not evaluated directly (‘missing values’)
for that cell in the corresponding tube it was contained in. Then, the calculation function of
the Infinicyt software was used to fill in the ‘missing values’, based on the ‘nearest
neighbour’ statistical principle, defined by the unique position of individual PCs the
multidimensional space created by the five common (backbone) parameters (FSC, SSC,
CD38, CD45 and CD19). Ultimately, the expression of all 23 phenotypic markers could be
analysed at the single PC level, and compared between PCs clustering into the specific
CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets. Markers differentially expressed
between the CD19+CD81+ (light blue), CD19−CD81+ (intermediate blue) and CD19−CD81−
(dark blue) subsets within BM normal PCs from healthy individuals (n = 10). Notched boxes
represent the 25th and 75th percentile values of the amounts of antigen mean fluorescence
intensity expression per BM PCs; the line in the middle and vertical lines correspond to the
median value and both the 10th and 90th percentiles, respectively.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 17
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
Figure 2.
Multiple myeloma (MM) patients’ survival according to the differentiation stage of
myeloma PC clones. Panels a and b show progression-free survival (PFS) and overall
survival (OS) for the overall series of MM patients (n = 225) grouped according to the
differentiation stage of clonal plasma cells (PCs) at diagnosis: more-differentiated
(CD19−CD81−), intermediate-differentiated (CD19−CD81+) and less-differentiated
(CD19+CD81+). Patients’ treatment consisted of either nine identical induction cycles with
bortezomib, melphalan, prednisone (VMP) followed by other nine cycles of lenalidomide
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 18
plus low-dose dexamethasone (Rd; n = 112), or alternating cycles of VMP and Rd for up to
18 courses (n = 113). The median follow-up of the series was 3 years. Panels c and d show
PFS and OS in patients with standard-risk cytogenetics (n = 154; all those cases without
t(4;14), t(14;16) and/or del(17p13)).
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 19
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
Figure 3.
Therapeutic selection at the MRD stage of myeloma PC subclones defined according to their
differentiation stage. (a) Correlation between the percentage of CD19 (black squares) and
CD81 (open circles) positive plasma cells (PCs) within total baseline (x axis) vs MRD (y
axis) clonal PCs in longitudinal bone marrow samples from 40 multiple myeloma (MM)
patients analysed at diagnosis and after therapy. (b) Schema showing the frequency of
patients following specific clonal dynamics according to the differentiation stage of
myeloma PCs from diagnosis to the MRD stage. Representative bivariate dot plot
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 20
Europe PMC Funders Author Manuscripts
histograms illustrating the patterns of CD19 vs CD81 expression in clonal PCs at diagnostic
(represented by lines corresponding to one and two SD) and at the MRD stage (red dots)
corresponding to four out of the eight patients that evolved from baseline more differentiated
(that is: CD19−CD81−) into intermediate-differentiated (that is: CD19−CD81+)
chemoresistant PC clones after therapy, ordered from left to right, denoting high to low
MRD levels, are also shown. Twelve out of the 30 patients displaying the same
differentiation stage during baseline and MRD monitoring attained CR, three out of the eight
cases with fully differentiated phenotypes at diagnosis showing intermediate stage
chemoresistant clonal PCs after therapy attained CR, and so did one out of the two patients
transitioned from a CD19−CD81+ into a CD19−CD81− phenotype.
Europe PMC Funders Author Manuscripts
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 21
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts
Figure 4.
Distinct PC differentiation subsets within individual patients show different mutation
profiles. Clonal plasma cells (PCs) corresponding to the intermediate- (CD19−CD81+) and
more-differentiated (CD19−CD81−) subsets were FACS-sorted from patients #1, #2, #4, #5
and #6 (a, b, d, e and f) for mutation analysis using a targeted-sequencing panel covering 77
genes; in patient #3 (c), mutations were investigated in less-differentiated (CD19+CD81+) vs
intermediate- (CD19−CD81+) and more-differentiated (CD19−CD81−) PC clones.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 22
Europe PMC Funders Author Manuscripts
Figure 5.
Europe PMC Funders Author Manuscripts
The sequential CpGs measured by HumanMethylation450 BeadChip for the CD81 gene. We
investigated the expression levels of CD19 and CD81 in a large panel of MM cell lines
(RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3, MM1S, MM1R, MM144, U266,
U266-DOX4, U266-LR7, SJR and MGG) and identified five cell lines positive for CD81
(RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3) in the absence of CD19; all the others
exhibited no expression for both CD19 and CD81 (data not shown). Afterward, under the
hypothesis that loss of CD81 expression could be due to epigenetic regulation of the CD81
gene, we investigated the DNA methylation profile of CD81 in the NCI-H929, JJN3 and
U266 cell lines (the first two positive for CD81 and the third negative). Accordingly, we
observed an inverse correlation between DNA methylation levels in the CpG island region of
the CD81 gene and the protein (antigen) expression level of CD81 in the three MM cell
lines. Interestingly, the DNA methylation levels in the CpG island region were also inversely
correlated with the DNA methylation levels in the gene body region of CD81. These results
indicate that an epigenetic mechanism of DNA methylation plays an important role in the
regulation of CD81 expression. The mean of the DNA methylation levels of the CpGs
located in the CpG island or gene body region of CD81 are also shown.
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 23
Table 1
Phenotypic features of patients with less-differentiated (that is, CD19+CD81+), intermediate-differentiated
Europe PMC Funders Author Manuscripts
(that is: CD19-CD81+) vs more-differentiated (that is, CD19-CD81-) plasma cell clones among newly
diagnosed multiple myeloma patients (n = 225)
CD19+CD81+ (%)
CD19-CD81+ (%)
CD19-CD81−(%)
P-value
CD38low
67
52
67
0.09
CD138low
33
31
31
0.99
CD27+
33
43
50
0.48
CD28+
17
20
35
0.04
CD45+
67
50
29
0.003
CD56+
77
76
75
0.85
CD117+
67
24
41
0.009
% of cases within subgroup
Europe PMC Funders Author Manuscripts
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 24
Table 2
Cytogenetic characteristics of patients with less-differentiated (that is: CD19+CD81+) and intermediate-
Europe PMC Funders Author Manuscripts
differentiated (that is: CD19-CD81+) vs more-differentiated (that is: CD19-CD81−) plasma cell clones among
newly diagnosed multiple myeloma patients (n = 169)
Genetic abnormality
PCs differentiation subset
CD19+
CD81+
(%)
CD19-CD81+
(%)
P-value
CD19-CD81−
(%)
Any
25
62
72
0.07
t(4;14)
0
24
17
NS
t(11;14)
0
68
36
0.03
t(14;16)
0
0
11
NS
+1q
25
41
54
NS
del(13q)
0
49
51
NS
del(17p)
0
13
8
NS
High-risk FISH
0
23
19
NS
Abbreviation: NS, not significant.
Europe PMC Funders Author Manuscripts
Leukemia. Author manuscript; available in PMC 2017 May 22.
Paiva et al.
Page 25
Table 3
Multivariate analyses including baseline disease features with univariate significant effect on PFS and/or OS
of newly diagnosed elderly myeloma patients included in the GEM2010MAS65 trial
Europe PMC Funders Author Manuscripts
OS
PFS
Age (< 75 vs ≥75 years)
HR
P
HR
P
1.3
0.21
2.7
0.001
ISS
1.2
0.50
1.9
0.16
Interphase FISH cytogenetics (standard- vs high-risk)
1.9
0.003
2.7
0.001
PC differentiation stage
1.7
0.005
2.1
0.006
Abbreviations: FISH, Fluorescence-in situ-hybridization; High-risk FISH, t(4;14), t(14;16) and/or del(17p13); ISS, International Staging System;
OS, overall survival; PC, plasma cell; PFS, progression-free survival.
Europe PMC Funders Author Manuscripts
Leukemia. Author manuscript; available in PMC 2017 May 22.